Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New CAR-T therapy aims to control Hard-to-Treat lymphoma

NCT ID NCT07360288

Disease control Sponsor: TICAROS Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called TC011 for adults with follicular lymphoma that has come back or not responded to at least two prior therapies. TC011 is a type of CAR-T cell therapy that targets cancer cells. The main goal is to see how many patients' tumors shrink or disappear after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ability to provide written informed consent. 2. Age ≥19 years at the time of screening. 3. Histologically confirmed follicular lymphoma Grade 1, 2, or 3a according to WHO 2017 classification. 4. Relapsed or refractory disease after at least two prior systemic therapies including rituximab. 5. ECOG performance status ≤2. 6. Life expectancy ≥12 weeks. 7. At least one measurable lesion (long diameter ≥1.5 cm). 8. Adequate hepatic, renal, hematologic, pulmonary, and cardiac function. 9. Eligible for leukapheresis and successful manufacture of TC011. 10. Agreement to use effective contraception for at least 6 months after TC011 infusion. Exclusion Criteria: 1. Histologic transformation to diffuse large B-cell lymphoma or follicular lymphoma Grade 3b. 2. Unresolved ≥Grade 2 toxicity from prior anticancer therapy (excluding hematologic abnormalities). 3. Active or prior malignancy within 2 years, except adequately treated non-melanoma skin cancer or carcinoma in situ. 4. Clinically significant cardiovascular disease within 6 months prior to screening. 5. Active central nervous system involvement by lymphoma. 6. Active uncontrolled infection, including HBV, HCV, HIV, or syphilis (protocol-defined exceptions apply). 7. Active autoimmune or inflammatory neurologic disease. 8. Rapidly progressive disease requiring urgent therapy. 9. Prior treatment with anti-CD19 therapy, adoptive T-cell therapy, gene therapy, or allogeneic stem cell transplantation. 10. Major surgery within 4 weeks prior to screening. 11. Use of investigational agents within 4 weeks prior to screening. 12. Known hypersensitivity to components of TC011. 13. Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Follicular lymphoma (FL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Follicular lymphoma (FL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.